drugset
drugset / Trial / NCT03174613

A Study To Evaluate The Safety, Pharmacokinetics/Pharmacodynamics (PK/PD) and Food Effect Of LC51-0255

NCT03174613 ↗

Phase 1 Completed 100 enrolled LG Chem
RandomizedParallel-groupDouble-blindBasic science

Summary

1. To evaluate the safety and tolerability of LC51-0255 in healthy male subjects 2. To evaluate the pharmacokinetic/pharmacodynamics characteristics (PK/PD) of LC51-0255 in healthy male subjects 3. To evaluate bioavailability of LC51-0255

Timeline

Start
2017-05-31
Primary completion
2019-06-12
Completion
2019-07-11

Drugs

EvaluationDrugModalityDoseRoute
Subject LC51-0255 Unknown 0.25 mg Oral
Subject LC51-0255 Unknown 0.5 mg Oral
Subject LC51-0255 Unknown 1 mg Oral
Subject LC51-0255 Unknown 2 mg Oral
Subject LC51-0255 Unknown 4 mg Oral
Subject LC51-0255 Unknown 8 mg Oral

Indications

No indication recorded.